Google
ONC 株価分析 — BEIGENE, LTD. (Healthcare >> Biotechnology)
ONC に関するよくある質問
ONCのPER（株価収益率）は？
BEIGENE, LTD.（ONC）は現在PER 65.14倍で取引されています。
ONCのROE（自己資本利益率）は？
BEIGENE, LTD.のROEは10.78%です。
ONCの配当利回りは？
BEIGENE, LTD.の配当利回りは0.00%です。
ONCの品質スコア（Quality Score）は？
当社のAIはONCの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ONCは今が買い時ですか？
当社AIのタイミングスコアは100点中87点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ONCはどのセクターに属しますか？
BEIGENE, LTD.はHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
ONC AI Analysis Summary
Our AI summary for ONC: BEIGENE, LTD. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 65.14, ROE of 10.78%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 316.01
Price
-6.07
(-1.88%)
Day Change
|
|
|---|
ONC, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 53 |
| Magic Formula Rank by ROA |
2658
|
| Magic Formula Rank by ROE |
2658
|
| Magic Formula Rank by ROIC |
1904
|
| Price | 316.01 |
| PBV / Sector |
7.02 / 5.20
|
| Earning Per Share | 4.85 |
| PE / Sector |
65.14 / 19.97
|
| PEG or PE/Growth / Sector |
-0.87 / 1.22
|
| Average 1M Daily Value |
115.82 M
GREAT
|
| Average 1W Daily Value |
77.92 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:16 |
| Symbol | ONC |
| Name | BEIGENE, LTD. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 94.90 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 33,416.19 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 94 Aeschengraben 27, Basel, Switzerland, 4051
Phone: 41 61 685 19 00
Website: https://beonemedicines.com
Employees: 12,000
Sector: Healthcare >> Biotechnology
Description: BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
